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Case 22-2019: A 65-Year-Old Woman with Myopathy
To the Editor: The case reported by Freeman
et al. (July 18 issue)1 contains conclusions that
may perpetuate misconceptions. The patient had
acute rhabdomyolysis and necrotizing autoimmune myositis, but the connection with statins is
unlikely.
In this patient, myopathy started 2 weeks after coryza and cough; this suggests a preceding
viral infection, which is a more likely trigger of
necrotizing autoimmune myositis2 than atorva
statin, which had been initiated 6 months previously. Statins can rarely lead to acute myotoxicity, but the contention that they induce
anti-HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase)–mediated autoimmunity is un
substantiated and disputed.3 HMGCR is normally
expressed in regenerating rather than necrotic
fibers, and there is no evidence that it induces
muscle-fiber necrosis or triggers autoimmunity,
especially since HMGCR is a ubiquitous cytoplasmic antigen that is not accessible to antiHMGCR antibodies.4 HMGCR is expressed in
normal myotubes, but anti-HMGCR IgG does
not induce myotubular necrosis5 and does not
explain pathogenicity.4 Most important, antiHMGCR autoantibodies are not statin-specific
because they are most frequently seen in patients with paraneoplastic, viral, or other forms
of necrotizing autoimmune myositis who have
not received statins.6
In the few patients in whom necrotizing autoimmune myositis does develop after receipt of
statins for years, the association is more of a
chance phenomenon, considering that necrotizing autoimmune myositis is now the most common inflammatory myopathy2,4 and that 25% of
Americans older than 40 years of age take
statins. The authors’ conclusions could deprive
the patient, as well as others with a similar presentation, of a helpful drug.
n engl j med 381;17
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To the Editor: We would like to expand on the
discussion by Freeman et al. on statin-associated
autoimmune myopathy with autoantibodies
against HMGCR in a patient who had been prescribed a statin medication. First, we would note
that this disease may also be associated with a
dietary source of statins, such as red yeast rice or
oyster mushrooms.1 Second, since at least 25% of
patients with anti-HMGCR–associated autoimmune myopathy have no known exposure to
statins,2 testing for anti-HMGCR autoantibodies
may be considered in other patients with myopathy. This includes adults and children with clinical presentations that are consistent with genetic
muscle disease but no known genetic defect;
some of these patients have anti-HMGCR–associated autoimmune myopathy that responds to
treatment.3 Third, reinitiation of statins is con-
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traindicated in patients with statin-associated
autoimmune myopathy. However, the use of proprotein convertase subtilisin–kexin type 9 (PCSK9)
inhibitors appears to be safe in this patient population and may be considered in patients with
clinically significant cardiovascular risk factors.4
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illness is a potential trigger, we did not find
compelling literature linking viral illness with
anti-HMGCR autoantibodies. Although the duration of statin use before anti-HMGCR myopathy
is variable, 2 or more years of exposure is frequently reported. Thus, the time course in this patient is consistent with a statin-associated event.2,3
We agree that Koch’s postulates for causality are
not satisfied with regard to the role of statins or
HMGCR autoantibodies in causing necrotizing
autoimmune myopathy; until there is stronger
evidence, it may be better to view the condition
as statin-associated rather than statin-induced.
We do not agree, however, with rechallenging patients with statins; this perspective was supported in a recent review article stating that all five
patients who were rechallenged had adverse effects.4 In our opinion, rechallenging a patient
with a statin would require conclusive proof that
a statin was not implicated in the disorder. Given
the very refractory nature of necrotizing autoimmune myopathy, we think alternative cholesterollowering therapy with the use of PCSK9 antibodies or ezetimibe should be the recommended
treatment for a patient after the development of a
statin-associated anti-HMGCR myopathy.
We thank Pinal-Fernandez and Mammen for
their comments. These letters raise important
issues in understanding this rare immune-mediated myopathy.
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